2024
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial
Qadri F, Khanam F, Zhang Y, Biswas P, Voysey M, Mujadidi Y, Kelly S, Bhuiyan A, Rajib N, Hossen I, Rahman N, Islam S, Pitzer V, Kim Y, Clemens J, Pollard A, Liu X. 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial. The Lancet 2024, 404: 1419-1429. PMID: 39396349, DOI: 10.1016/s0140-6736(24)01494-6.Peer-Reviewed Original ResearchConceptsTyphoid conjugate vaccineJapanese encephalitis vaccineVaccine effectivenessRandomised controlled trialsConjugate vaccineFollow-upTyphoid feverControlled trialsVaccine protectionChildren aged 9 monthsIncreased risk of typhoid feverAnti-Vi IgGRisk of typhoid feverVaccine efficacy dataTest-negative designAged 9 monthsUnvaccinated individualsHigh-burden countriesIncidence rate ratiosAnalyses of vaccine effectivenessSingle-doseSingle doseDecay of antibodiesSubgroup analysisBooster doseEstimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study
Hartner A, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, de Villiers M, Ferrari M, Fraser K, Fu H, Hallett T, Hinsley W, Jit M, Karachaliou A, Moore S, Nayagam S, Papadopoulos T, Perkins T, Portnoy A, Minh Q, Vynnycky E, Winter A, Burrows H, Chen C, Clapham H, Deshpande A, Hauryski S, Huber J, Jean K, Kim C, Kim J, Koh J, Lopman B, Pitzer V, Tam Y, Lambach P, Sim S, Woodruff K, Ferguson N, Trotter C, Gaythorpe K. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study. The Lancet Global Health 2024, 12: e563-e571. PMID: 38485425, PMCID: PMC10951961, DOI: 10.1016/s2214-109x(23)00603-4.Peer-Reviewed Original ResearchConceptsCatch-up activitiesVaccine-preventable disease burdenCatch-upVaccine Impact Modelling ConsortiumImmunisation servicesMiddle-income countriesEffectiveness of HPV vaccinationVaccine effectivenessAffected cohortBill & Melinda Gates FoundationImmunisation coverageLow-incomeLong-term effectsWHO-UNICEFDisease burdenVaccination coverageCalendar yearImmunisation effortsMelinda Gates FoundationMitigation measuresCountriesYears of vaccinationYellow fever vaccine
2023
Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis
Khanam F, Kim D, Liu X, Voysey M, Pitzer V, Zaman K, Pollard A, Qadri F, Clemens J. Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis. EClinicalMedicine 2023, 58: 101925. PMID: 37090439, PMCID: PMC10114505, DOI: 10.1016/j.eclinm.2023.101925.Peer-Reviewed Original ResearchVaccine herd protectionCluster-randomised trialHerd protectionTransmission of typhoidVi-TTTyphoid feverChildren 9 monthsVi-tetanus toxoidMonths of followJapanese encephalitis vaccineYears of ageTotal vaccine effectivenessUrban Bangladeshi childrenVaccine effectivenessEncephalitis vaccineStudy populationBangladeshi childrenTreatment centersCluster residentsIndirect effectivenessMelinda Gates FoundationTrialsVaccineAnalysis of subpopulationsFever
2022
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel
Prunas O, Weinberger D, Pitzer V, Gazit S, Patalon T. Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel. Clinical Infectious Diseases 2022, 76: 113-118. PMID: 36484301, PMCID: PMC10202431, DOI: 10.1093/cid/ciac315.Peer-Reviewed Original ResearchConceptsMaccabi Healthcare ServicesBNT162b2 vaccineSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionPositive polymerase chain reaction testSARS-CoV-2 infectionPfizer BNT162b2 vaccineCoronavirus 2 infectionVaccine-induced immunityVaccine-induced protectionPolymerase chain reaction testIncidence of infectionCoronavirus disease 2019COVID-19Chain reaction testShort-term effectivenessCase-control designLong-term effectivenessVaccine effectivenessSymptomatic infectionLong-term protectionDisease 2019Delta variant
2018
Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction
Bennett A, Pollock L, Jere K, Pitzer V, Parashar U, Tate J, Heyderman R, Mwansambo C, French N, Nakagomi O, Iturriza-Gomara M, Everett D, Cunliffe N, Bar-Zeev N, Consortium F. Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction. Vaccine 2018, 36: 7142-7148. PMID: 29887320, PMCID: PMC6238204, DOI: 10.1016/j.vaccine.2018.04.030.Peer-Reviewed Original ResearchConceptsPost-vaccine introductionPrevalence of rotavirusVaccine effectivenessRotavirus prevalenceAcute gastroenteritisVaccine introductionRotavirus hospitalisationsVaccine coverageEfficacy estimatesAdjusted vaccine effectivenessRotavirus vaccine introductionYears of ageUse of vaccinesUnvaccinated infantsRotavirus diarrheaRotavirus diseaseUnvaccinated childrenReferral hospitalRoutine immunisationMalawian childrenSevere diarrheaStool samplesImportant causePoisson regressionHospitalisation
2015
Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?
Pitzer VE, Bilcke J, Heylen E, Crawford FW, Callens M, De Smet F, Van Ranst M, Zeller M, Matthijnssens J. Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium? Scientific Reports 2015, 5: 18585. PMID: 26687288, PMCID: PMC4685644, DOI: 10.1038/srep18585.Peer-Reviewed Original ResearchConceptsVaccine introductionStrain-specific vaccine effectivenessVaccine-derived immunityRotavirus vaccine introductionVaccine-induced immunityAbsence of vaccinationRotavirus populationLarge-scale vaccinationDistribution of genotypesRotavirus gastroenteritisVaccine effectivenessHomotypic strainHospitalization dataPredominant rotavirusStrain replacementVaccinationVaccineImmunityInfectionViral populationsPopulationGastroenteritisYearsIncidenceRotavirus